IP Group's Oxford Nanopore in advanced development on SARS Cov-2 test
IP Group
47.25p
16:35 25/04/24
Intellectual property developer IP Group said its portfolio company Oxford Nanopore Technologies was in advanced development of a new generation of end-to-end test (assay) for the detection of the virus that causes Covid-19.
Financial Services
13,969.36
17:09 25/04/24
FTSE 250
19,601.98
17:09 25/04/24
FTSE 350
4,434.34
17:09 25/04/24
FTSE All-Share
4,387.94
16:49 25/04/24
IP, which holds 16.4% of Oxford Nanopore, said the “LamPORE” test, which finds SARS-CoV-2, is designed to be “rapid, low cost, and scalable to cater to on-demand analysis of smaller sample numbers, to very large numbers of samples”.
LamPORE is based on Oxford Nanopore's DNA/RNA sequencing technology and seeks to understand whether a sample currently contains SARS-CoV-2, rather than detecting antibodies that may indicate a previous infection, the company added.